- The FDA has approved Sanofi SA's SNY fexinidazole as the first all-oral treatment for both stages of the Trypanosoma brucei gambiense form of sleeping sickness in patients six years of age and older and weighing at least 20 kg.
- Sleeping sickness is a parasitic disease transmitted by the bite of an infected tse-tse fly.
- Fexinidazole is indicated as a 10-day once-a-day treatment.
- Price Action: SNY shares are down 1.79% at $51.06 during the market session on the last check Monday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
